Skip to main content
logo
Kailera Therapeutics, Inc. (KLRA)
NASDAQ: KLRA · Real-Time Price · USD
13.25
+0.28 (2.16%)
Nov 9, 2026, 9:43 AM EST - Market open

Kailera Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Sep '26 Dec '25 Dec '24
Net Income
-348.24-148.96-329.57
Depreciation & Amortization
0.430.310.08
Loss (Gain) From Sale of Investments
-5.84-1.73-
Stock-Based Compensation
25.7210.941.41
Other Operating Activities
1.532.44139.5
Change in Accounts Payable
6.84.693.01
Change in Other Net Operating Assets
-5.9812.090.61
Operating Cash Flow
-325.59-120.21-184.95
Operating Cash Flow Growth
---

Investing Activities

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Sep '26 Dec '25 Dec '24
Capital Expenditures
-1.65-2.09-0.39
Investment in Securities
-826.17-490.51-
Investing Cash Flow
-827.82-492.6-0.39

Financing Activities

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Sep '26 Dec '25 Dec '24
Long-Term Debt Issued
-100-
Net Debt Issued (Repaid)
-100-
Issuance of Common Stock
669.360.1-
Other Financing Activities
-6.21-0.32-
Financing Cash Flow
1,162598.66448.11

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Sep '26 Dec '25 Dec '24
Net Cash Flow
8.62-14.15262.77

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Sep '26 Dec '25 Dec '24
Free Cash Flow
-327.23-122.3-185.35
Free Cash Flow Growth
---
Free Cash Flow Per Share
-2.52-6420.52-
Levered Free Cash Flow
--59.89-
Unlevered Free Cash Flow
--59.89-

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Sep '26 Dec '25 Dec '24
Change in Working Capital
0.8216.783.62
SEC Filings: 10-K · 10-Q